Telcon RF Pharmaceutical텔콘RF제약

Telcon RF Pharmaceutical is a small KOSDAQ company with ₩61.8B trailing revenue, near-breakeven operating profit, a large net loss, and a share price down 74.7% over the past year.

The company makes RF connectors and cable assemblies for wireless equipment, is expanding into optical products, and runs a pharmaceutical contract manufacturing business. Trailing twelve-month revenue to H1 2026 was ₩61.8B with operating income of about ₩0.4B, but net loss was ₩17.5B. At ₩2,190 the market cap is about ₩20.8B, and the stock trades at roughly 0.3 times book value.

What stands out

• Revenue grew 14% in 2025 to ₩43.2B, and the 2025 operating margin improved to 1.7%, but the company still posted a ₩11.5B net loss that year.
• Trailing net margin is -28.3% and ROE is -22.4%, so the profit line remains well below operating income.
• Cash of ₩17.5B against borrowings of ₩1.1B, with liabilities at 88.2% of equity; trailing free cash flow was only about ₩47M.
• Recent filings include a major sales or supply contract (2 October 2026), a decision on early acquisition of the company's own convertible bonds (29 September 2026), and several conversion price adjustments and a largest-shareholder lock-up in July 2026.
• No news headlines were included in the data, and foreign ownership is 0%.

What to watch

• The half-year report and any follow-up filings on the convertible bond buyback, since conversion price changes can affect share count.
• Lock-up expiry for the largest shareholder, which the July filings say has been implemented; the data does not give its timing.
• Whether the new major contract and optical product growth translate into sustained operating profit and positive net income; the data does not include guidance or forecasts.